United Therapeutics Corporation

United Therapeutics Corporation is a leading biotechnology company dedicated to developing and commercializing innovative therapies for patients suffering from chronic and life-threatening diseases, with a particular focus on pulmonary arterial hypertension (PAH). The company's robust product portfolio includes Tyvaso, available as both an inhaled solution and a dry powder formulation, and Remodulin, an injectable treatment, both designed to manage PAH symptoms and improve exercise capacity. Orenitram, an oral tablet form of treprostinil, further supports PAH patients by aiming to delay disease progression. United Therapeutics also offers Adcirca, an oral medication that enhances exercise ability in PAH patients, and Unituxin, a monoclonal antibody for treating high-risk neuroblastoma. Beyond its current offerings, the company is actively engaged in a promising pipeline of development-stage products, including RemoPro and Ralinepag for PAH, Aurora-GT gene therapy for lung blood vessel regeneration, and Nebulized Tyvaso for idiopathic pulmonary fibrosis. Strategic collaborations with entities like DEKA Research & Development Corp. and MannKind Corporation underscore United Therapeutics' commitment to advancing drug delivery systems and novel therapeutic agents, solidifying its position as a key innovator in the specialty pharmaceutical landscape.